Alyeska Investment Group
KRTX

Alyeska Investment Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Alyeska Investment Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-45,160
Closed -$737K – 508
2019
Q3 		$737K Sell
45,160
-25,000
-36% -$486K 0.01% 341
2019
Q2 		$1.41M Buy
+70,160
New +$1.4M 0.02% 353

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Alyeska Investment Group's KRTX Position: Q4 2019 in Review

Alyeska Investment Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2019, closing a stake of 45,160 shares — an estimated $737K sold.

Alyeska Investment Group first reported a position in KRTX in Q2 2019 and held it in 2 quarters. The position peaked at $1.41M in Q2 2019. 85 funds tracked by Wall St. Rank hold KRTX as of Q4 2019.

  • Alyeska Investment Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Alyeska Investment Group sold 45,160 Karuna Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $737K.
  • Alyeska Investment Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Alyeska Investment Group's Karuna Therapeutics, Inc. Common Stock position peaked at $1.41M in Q2 2019.
  • 85 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Alyeska Investment Group's 13F filing for Q4 2019, filed 14 Feb 2020.